Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
![Actelion](https://trials-media.s3.amazonaws.com/orgs/actelion.jpeg)
About this trial
This is an interventional treatment trial for Pulmonary Arterial Hypertension focused on measuring STEP, PAH, iloprost, inhalation, prostacyclin
Eligibility Criteria
Inclusion Criteria: Diagnosis of PAH due to PPH, connective tissue disease, HIV, or repaired (≥ 1 year) ASD, VSD, or PDA NYHA Functional Class III or IV On bosentan for at least 16 weeks, with the dose stable (maximum dose 125 mg BID) for at least 8 weeks Age 12-75 years, of either gender Six minute walk distance 100-425 meters at Baseline Exclusion Criteria: Any new long-term treatment for PAH added within the last 4 weeks Any therapy with a PDE (phosphodiesterase), L -arginine or a prostaglandin, concurrently, or within the last 4 weeks PAH related to chronic thromboembolic disease, portopulmonary disease, or any etiology other than PPH, connective tissue disease, HIV, or repaired ASD, VSD, or PDA
Sites / Locations
- University of Alabama at Birmingham
- UCSD Medical Center
- Stanford University Medical Center
- UCSF Medical Center
- Harbor-UCLA Medical Center
- The Children's Hospital
- University of Colorado HSC
- Rush Heart Institute, Center for Pulmonary Heart Disease
- Johns Hopkins University
- University of Michigan
- Mayo Clinic
- Columbia University Medical Center
- Duke University Medical Center
- University of Pittsburgh
- Vanderbilt University Medical Center
- Baylor College of Medicine
- Latter Day Saints Hospital